Emugrobart Fails in 259-Patient Muscle Disease Trial
Roche has discontinued development of its drug candidate emugrobart for spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy. The decision, announced on March 20, 2026, followed underwhelming results from the Phase 2/3 MANATEE study, which enrolled 259 patients. According to Roche subsidiary Genentech, the anti-myostatin therapy "did not consistently deliver the improvements we hoped for in muscle growth and motor function."
The company emphasized that the trial was not terminated due to safety issues, as emugrobart remained well-tolerated. However, the failure to demonstrate a clear clinical benefit represents a significant setback for Roche's neuromuscular pipeline. Patients in the MANATEE study will be transitioned to Evrysdi, Roche's approved SMA treatment.
Discontinuation Clears Market for Rival Scholar Rock
Roche's exit from the space creates a direct commercial path for Scholar Rock and its competing myostatin blocker, apitegromab. Analysts at Truist Securities noted the move “sets the stage for apitegromab domination,” leaving Scholar Rock with “no competition for future market share” in this specific class of SMA therapy. This development marks a sharp reversal of fortune for Scholar Rock, which faced a regulatory setback in September 2025 when the FDA rejected its application for apitegromab due to manufacturing issues at a third-party facility.
With those manufacturing problems reportedly nearing resolution, investor focus is now shifting to apitegromab's commercial opportunity. BMO Capital Markets analysts stated that as the manufacturing concerns are resolved, Roche’s withdrawal could be a significant boon for Scholar Rock's initial sales in the SMA market.
Roche Pivots Emugrobart Program Toward Obesity
While development for muscle diseases has been terminated, Roche is not abandoning the emugrobart asset entirely. The pharmaceutical giant confirmed it will continue to develop the anti-myostatin antibody for the treatment of obesity. A mid-stage study for this indication is already underway, with a potential regulatory filing projected for 2028 at the earliest. This strategic pivot allows Roche to salvage its investment in the molecule by targeting the highly lucrative obesity market, even as it cedes the neuromuscular field to competitors.
Edgen Stock·Mar 23 2026, 08:38
